Medicine

This archive tracks meaningful advances in medicine — from new treatments and diagnostics to health policy wins and research breakthroughs. Stories here focus on what is working, who is driving progress, and how medical science is improving lives across the globe.

Cancer cells, for article on pancreatic cancer drug

U.S. FDA approves breakthrough pancreatic cancer drug that doubles survival

By / / Good News For Humankind

Pancreatic cancer has long been one of medicine’s most stubborn opponents, with a five-year survival rate of just 13 percent and few good options once chemotherapy stops working. The newly approved drug daraxonrasib offers patients a targeted second chance — blocking a specific protein that drives cancer cell growth rather than flooding the body with toxic agents. Clinical trial results showed a meaningful survival advantage over standard chemotherapy, though pricing remains unannounced and cost could limit who actually benefits. Still, the KRAS-targeting science behind this drug may eventually open new doors for other hard-to-treat cancers too.

A researcher examining a vial in a medical laboratory for an article about Type 1 diabetes cure research

Stanford researchers take a major step toward curing Type 1 diabetes

By / / Good News For Humankind

Type 1 diabetes cure research took a significant step forward as Stanford University scientists demonstrated a hybrid approach combining gene therapy and immune system retraining to protect insulin-producing beta cells. Rather than simply replacing destroyed cells, the method attempts to retrain the immune system to stop attacking them — targeting the root cause of the disease. In preclinical animal trials, the approach restored normal blood sugar regulation without requiring lifelong immunosuppressant drugs. For the millions living with this demanding, costly condition, the findings represent meaningful progress toward a functional cure.

A researcher examines cancer cells under a microscope for an article about pancreatic tumor regression — 14 words.

Spanish researchers achieve full pancreatic tumor regression in a mouse model study

By / / Good News For Humankind

Pancreatic tumor regression achieved in mice marks a rare and significant breakthrough in one of oncology’s most stubborn challenges. Researchers at Spain’s National Cancer Research Centre induced complete disappearance of established pancreatic tumors by reprogramming the tumor microenvironment, allowing the immune system to recognize and destroy cancer cells. Pancreatic cancer kills the vast majority of patients it affects, with a five-year survival rate below 12%, partly because dense tissue surrounding tumors blocks treatment and hides cancer from immune defenses. While mouse results don’t guarantee human success, this proof of concept signals that full regression in this disease is biologically possible.

Close-up of a researcher examining brain scan imagery for an article about Alzheimer's reversal in mice

American scientists fully reverse Alzheimer’s in mice in a promising study

By / / Good News For Humankind

Alzheimer’s reversal in mice has been achieved by a team of American researchers who eliminated amyloid plaques and tau tangles while restoring measurable memory and spatial reasoning in treated animals. Using precision gene therapy to suppress overactive neurodegeneration pathways, the team reduced brain inflammation and reactivated neurons that had gone functionally silent. The findings matter because no existing treatment reverses Alzheimer’s — they only slow it. What makes this significant is that recovery, not merely stabilization, was observed, challenging longstanding assumptions about irreversible brain damage and strengthening the case that neuroplasticity could become a realistic therapeutic target.

A nurse-midwife consulting with a pregnant patient in a rural clinic for an article about autonomous midwifery practice

Virginia gives nurse-midwives the right to practice without physician oversight

By / / Good News For Humankind

Certified nurse-midwives in Virginia can now practice independently after the state eliminated its physician supervision requirement. The change addresses a critical gap in maternity care, particularly in rural counties where obstetric services are scarce or entirely absent. Research consistently shows that midwife-led care for low-risk pregnancies produces strong outcomes for mothers and newborns while reducing unnecessary medical interventions. Virginia joins a growing number of states aligning licensing laws with full practice authority standards, reflecting national momentum to expand access to qualified maternal care providers.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA’s approval of Journavx (suzetrigine), a first-in-class non-opioid pain drug, marks the most significant shift in acute pain treatment in over two decades. Developed by Vertex Pharmaceuticals, the drug blocks a specific sodium channel in the peripheral nervous system, stopping pain signals before they reach the brain without engaging the opioid pathways linked to addiction and overdose. Two rigorous clinical trials confirmed its effectiveness for moderate to severe acute pain. With more than 500,000 opioid overdose deaths in the U.S. since 1999, this approval offers patients and doctors a genuinely new choice — one that treats real pain without the shadow of dependence.

Depiction of MRSA bacteria up close, for article on MRSA antibiotic discovery

MIT scientists discover the first new antibiotics in over 60 years using AI

By / / Good News For Humankind

A new class of antibiotics has been discovered for the first time in more than 60 years, and artificial intelligence helped get us there. MIT researchers trained deep-learning models to sift through roughly 12 million chemical compounds, eventually landing on two promising candidates that each cut MRSA populations tenfold in mouse studies. Just as importantly, the team built their AI to be transparent, so scientists can actually see why certain molecules work. That matters because the same framework could be turned loose on other drug-resistant infections, offering real hope against superbugs that kill tens of thousands of people every year.

Self-portrait of a woman with cancer and her children, for article on triple-negative breast cancer vaccine

Triple-negative breast cancer vaccine shows good response in first clinical trial of patients

By / / Good News For Humankind

A new breast cancer vaccine sparked an immune response in three out of four patients during its first human safety trial — with no serious side effects reported. The Cleveland Clinic study targeted triple-negative breast cancer, an aggressive subtype that resists most standard treatments and disproportionately affects younger women and Black women. The vaccine works by training the immune system to recognize a lactation protein found in most TNBC tumors but absent in healthy adult tissue, giving immune cells a clear target. Next come larger trials testing whether it can prevent recurrence and even attack active tumors. It’s an early but hopeful signal in the growing field of cancer immunotherapy, where teaching the body to find cancer itself is reshaping what treatment can look like.

Vials and syringes in a lab, for article on not-for-profit drug access

Pfizer to sell all its drugs in 45 low-income countries at non-profit price

By / / Good News For Humankind

Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.